NLS Pharmaceutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-03-31 | 2023-06-30 |
|---|---|---|---|
Gross Profit | -5 | -5 | -5 |
EBITDA | -1,943 | -4,408 | -7,543 |
EBIT | -1,948 | -4,408 | -7,549 |
Net Income | -2,035 | -4 | -7,612 |
Free Cash Flow | -1,530 | -2 | -7,296 |
Cash | 552 | 897 | 1,651 |
Basic Shares | 41,945 | 32,428 | 38,176 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -11 | -11 | -10 | |
EBITDA | -11,795 | -15,470 | -11,850 | -2,299 |
EBIT | -11,807 | -15,482 | -11,860 | -4,598 |
Net Income | -12,172 | -16,495 | -11,946 | -2,861 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -9,684 | -13,879 | -14,975 | -729 |
Cash | 897 | 8,948 | 5,431 | 93 |
Basic Shares | 38,176 | 19,682 | 14,748 | 4,819 |
